SCHEMBL14980372

SCHEMBL14980372

CN1CCC(Nc2ccncc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.64
AXL P30530 1/20 0.47
TLR8 Q9NR97 1/20 0.46
TLR7 Q9NYK1 1/20 0.46
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
IKBKB O14920 1/20 0.43
HRH4 Q9H3N8 2/20 0.43
ROCK1 Q13464 1/20 0.42
ITK Q08881 1/20 0.42
KAT2B Q92831 1/20 0.41
BRD4 O60885 1/20 0.41
ATAD2 Q6PL18 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
IDH2 P48735 1/20 0.41
CDK1 P06493 1/20 0.40
CDK4 P11802 1/20 0.40
CCNB1 P14635 1/20 0.40
CCNA2 P20248 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10372739 0.82 CTSD (0.48) POLBROCK1DRD2DRD3
SCHEMBL14409570 0.81 POLB (0.41) POLBCARM1PRMT6ROCK1KAT2B
SCHEMBL2674960 0.81 POLB (0.68) POLBCARM1PRMT6DRD3IDH2
SCHEMBL16219449 0.81 POLB (0.42) POLBAXLTLR8TLR7CARM1
SCHEMBL6026773 0.81 KDM4E (0.56) POLBCARM1PRMT6ROCK1DRD2
SCHEMBL19464791 0.81 WHR1 (0.46) POLBTLR8TLR7ROCK1
SCHEMBL3963182 0.80 DRD2 (0.52) POLBHRH4ROCK1DRD2DRD3
SCHEMBL22545891 0.80 KMT2A (0.50) POLBROCK1KAT2B
SCHEMBL27717981 0.80 SIGLEC9 (0.54) POLBIDH2KEAP1NFE2L2
SCHEMBL1409682 0.79 POLB (0.71) POLBAXLCARM1PRMT6ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 POLB 159/4885AXL 3077/4885TLR8 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.